Telomere Maintenance Mechanisms in Cancer: Clinical Implications

被引:65
作者
Reddel, Roger R. [1 ,2 ]
机构
[1] Childrens Med Res Inst, Westmead, NSW 2145, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
基金
英国医学研究理事会;
关键词
Alternative lengthening of telomeres; cancer; diagnosis; prognosis; telomerase; telomeres; therapy; TERT PROMOTER MUTATIONS; IMMORTAL HUMAN-CELLS; PROMYELOCYTIC LEUKEMIA BODIES; DNA-DAMAGE RESPONSE; HUMAN BREAST-CANCER; REVERSE-TRANSCRIPTASE; G-QUADRUPLEX; CLINICOPATHOLOGICAL PARAMETERS; HOMOLOGOUS RECOMBINATION; ALTERNATIVE MECHANISM;
D O I
10.2174/1381612820666140630101047
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The presence of immortal cell populations with an up-regulated telomere maintenance mechanism (TMM) is an almost universal characteristic of cancers, whereas normal somatic cells are unable to prevent proliferation-associated telomere shortening and have a limited proliferative potential. TMMs and related aspects of telomere structure and function therefore appear to be ideal targets for the development of anticancer therapeutics. Such treatments would be targeted to a specific cancer-related molecular abnormality, and also be broad-spectrum in that they would be expected to be potentially applicable to most cancers. However, the telomere biology of normal and malignant human cells is a relatively young research field with large numbers of unanswered questions, so the optimal design of TMM-targeted therapeutic approaches remains unclear. This review outlines the opportunities and challenges presented by telomeres and TMMs for clinical management of cancer.
引用
收藏
页码:6361 / 6374
页数:14
相关论文
共 50 条
[41]   Telomere maintenance and the DNA damage response: a paradoxical alliance [J].
Harman, Ashley ;
Bryan, Tracy M. .
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
[42]   On BLM helicase in recombination-mediated telomere maintenance [J].
Rezazadeh, Sarallah .
MOLECULAR BIOLOGY REPORTS, 2013, 40 (04) :3049-3064
[43]   PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications [J].
Wang, Xueting ;
Zeng, Xianhu ;
Li, Dan ;
Zhu, Chunrong ;
Guo, Xusheng ;
Feng, Lingxin ;
Yu, Zhuang .
BIOMEDICINE & PHARMACOTHERAPY, 2022, 153
[44]   Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications [J].
Li, Zhiming ;
Zhu, Wei-Guo .
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2014, 10 (07) :757-770
[45]   Telomere length and telomerase activity in non-small cell lung cancer prognosis: clinical usefulness of a specific telomere status [J].
Tamara Fernández-Marcelo ;
Ana Gómez ;
Irene Pascua ;
Carmen de Juan ;
Jacqueline Head ;
Florentino Hernando ;
Jose-Ramón Jarabo ;
Joaquín Calatayud ;
Antonio-José Torres-García ;
Pilar Iniesta .
Journal of Experimental & Clinical Cancer Research, 34
[46]   Caloric restriction and cancer: molecular mechanisms and clinical implications [J].
Meynet, Ophelie ;
Ricci, Jean-Ehrland .
TRENDS IN MOLECULAR MEDICINE, 2014, 20 (08) :419-427
[47]   The role of circadian clocks in cancer: Mechanisms and clinical implications [J].
Liu, Huiwen ;
Liu, Ying ;
Hai, Rihan ;
Liao, Weihua ;
Luo, Xiangjian .
GENES & DISEASES, 2023, 10 (04) :1279-1290
[48]   Telomere length and telomerase activity in non-small cell lung cancer prognosis: clinical usefulness of a specific telomere status [J].
Fernandez-Marcelo, Tamara ;
Gomez, Ana ;
Pascua, Irene ;
de Juan, Carmen ;
Head, Jacqueline ;
Hernando, Florentino ;
Jarabo, Jose-Ramon ;
Calatayud, Joaquin ;
Torres-Garcia, Antonio-Jose ;
Iniesta, Pilar .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2015, 34
[49]   Telomere Length Dynamics and the Evolution of Cancer Genome Architecture [J].
Cleal, Kez ;
Norris, Kevin ;
Baird, Duncan .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (02)
[50]   Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics [J].
Shou, Songting ;
Maolan, Ayidana ;
Zhang, Di ;
Jiang, Xiaochen ;
Liu, Fudong ;
Li, Yi ;
Zhang, Xiyuan ;
Geer, En ;
Pu, Zhenqing ;
Hua, Baojin ;
Guo, Qiujun ;
Zhang, Xing ;
Pang, Bo .
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2025, 14 (01)